97 related articles for article (PubMed ID: 30125597)
1. Affecting NF-κB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles.
Franiak-Pietryga I; Ostrowska K; Maciejewski H; Ziemba B; Appelhans D; Voit B; Jander M; Treliński J; Bryszewska M; Borowiec M
Toxicol Appl Pharmacol; 2018 Oct; 357():33-38. PubMed ID: 30125597
[TBL] [Abstract][Full Text] [Related]
2. Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: Targeting the BCR-signaling pathway.
Franiak-Pietryga I; Maciejewski H; Ostrowska K; Appelhans D; Voit B; Misiewicz M; Kowalczyk P; Bryszewska M; Borowiec M
Int J Biol Macromol; 2016 Jul; 88():156-61. PubMed ID: 26987432
[TBL] [Abstract][Full Text] [Related]
3. Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro-Preliminary Study.
Franiak-Pietryga I; Maciejewski H; Ziemba B; Appelhans D; Voit B; Robak T; Jander M; Treliński J; Bryszewska M; Borowiec M
Macromol Biosci; 2017 Nov; 17(11):. PubMed ID: 28762636
[TBL] [Abstract][Full Text] [Related]
4. PPI-G4 Glycodendrimers Upregulate TRAIL-Induced Apoptosis in Chronic Lymphocytic Leukemia Cells.
Franiak-Pietryga I; Ostrowska K; Maciejewski H; Appelhans D; Misiewicz M; Ziemba B; Bednarek M; Bryszewska M; Borowiec M
Macromol Biosci; 2017 May; 17(5):. PubMed ID: 27996200
[TBL] [Abstract][Full Text] [Related]
5. Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays.
Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Maciejewski H; Voit B; Kaczmarek A; Robak T; Klajnert-Maculewicz B; Cebula-Obrzut B; Smolewski P; Borowiec M; Bryszewska M
Anticancer Agents Med Chem; 2017; 17(1):102-114. PubMed ID: 27349446
[TBL] [Abstract][Full Text] [Related]
6. The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI.
Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Voit B; Szewczyk M; Góra-Tybor J; Robak T; Klajnert B; Bryszewska M
Mol Pharm; 2013 Jun; 10(6):2490-501. PubMed ID: 23641871
[TBL] [Abstract][Full Text] [Related]
7. Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL.
Franiak-Pietryga I; Ziemba B; Sikorska H; Jander M; Kuncman W; Danilewicz M; Appelhans D; Lewkowicz P; Ostrowska K; Bryszewska M; Borowiec M
Toxicol Appl Pharmacol; 2020 Sep; 403():115139. PubMed ID: 32687837
[TBL] [Abstract][Full Text] [Related]
8. Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.
Ziemba B; Sikorska H; Jander M; Kuncman W; Danilewicz M; Appelhans D; Bryszewska M; Borowiec M; Franiak-Pietryga I
Anticancer Agents Med Chem; 2020; 20(3):325-334. PubMed ID: 31738155
[TBL] [Abstract][Full Text] [Related]
9. Sugar-Modified Poly(propylene imine) Dendrimers Stimulate the NF-κB Pathway in a Myeloid Cell Line.
Jatczak-Pawlik I; Gorzkiewicz M; Studzian M; Appelhans D; Voit B; Pulaski L; Klajnert-Maculewicz B
Pharm Res; 2017 Jan; 34(1):136-147. PubMed ID: 27766462
[TBL] [Abstract][Full Text] [Related]
10. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
Hegde GV; Peterson KJ; Emanuel K; Mittal AK; Joshi AD; Dickinson JD; Kollessery GJ; Bociek RG; Bierman P; Vose JM; Weisenburger DD; Joshi SS
Mol Cancer Res; 2008 Dec; 6(12):1928-36. PubMed ID: 19074837
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer.
Ziemba B; Franiak-Pietryga I; Pion M; Appelhans D; Muñoz-Fernández MÁ; Voit B; Bryszewska M; Klajnert-Maculewicz B
Int J Pharm; 2014 Jan; 461(1-2):391-402. PubMed ID: 24361266
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
[TBL] [Abstract][Full Text] [Related]
14. Structural dependence of in vitro cytotoxicity, oxidative stress and uptake mechanisms of poly(propylene imine) dendritic nanoparticles.
Khalid H; Mukherjee SP; O'Neill L; Byrne HJ
J Appl Toxicol; 2016 Mar; 36(3):464-73. PubMed ID: 26671548
[TBL] [Abstract][Full Text] [Related]
15. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
16. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
17. Pyrrolidone Modification Prevents PAMAM Dendrimers from Activation of Pro-Inflammatory Signaling Pathways in Human Monocytes.
Janaszewska A; Gorzkiewicz M; Ficker M; Petersen JF; Paolucci V; Christensen JB; Klajnert-Maculewicz B
Mol Pharm; 2018 Jan; 15(1):12-20. PubMed ID: 29191014
[TBL] [Abstract][Full Text] [Related]
18. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Johnston JB; Kabore AF; Strutinsky J; Hu X; Paul JT; Kropp DM; Kuschak B; Begleiter A; Gibson SB
Oncogene; 2003 Nov; 22(51):8356-69. PubMed ID: 14614459
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
20. Poly(propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity.
Drzewińska J; Appelhans D; Voit B; Bryszewska M; Klajnert B
Biochem Biophys Res Commun; 2012 Oct; 427(1):197-201. PubMed ID: 22995301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
